INSILICO(03696.HK) Enters AI-Powered R&D Collaboration with SK Biopharmaceuticals, Total Potential Deal Value Exceeds USD2.5 Billion

NewTimeSpace News: On 22 June 2026, InSilico Medicine Cayman TopCo (03696.HK) issued a voluntary announcement disclosing an AI-powered drug discovery collaboration inked with SK Biopharmaceuticals Co., Ltd.

Within this partnership, InSilico Medicine will deploy its proprietary Pharma.AI platform, which integrates target validation, generative chemistry and molecular optimization capabilities, alongside its robust preclinical drug discovery expertise, to identify, design and optimize novel therapeutic candidates for neuroimmune indications. SK Biopharmaceuticals will leverage its deep-rooted R&D and clinical strengths in central nervous system neuroimmune diseases to lead all late-stage clinical development and global commercialization of pipeline assets generated from the collaboration.

Per contractual terms, InSilico Medicine may receive aggregate upfront and near-term milestone payments capped at USD18 million. The full potential value of the cooperation exceeds USD2.5 billion, consisting of multi-layered development, regulatory approval and commercial sales milestones, as well as single-digit percentage royalties calculated on net sales once products hit the market.

SK Biopharmaceuticals is a global biotech firm focused on the discovery, clinical development and commercialization of innovative therapies for central nervous system and other disease areas. It made history as the first South Korean pharmaceutical enterprise to independently complete end-to-end innovative drug R&D and commercialization in the U.S., with its anti-epileptic flagship product XCOPRI® (cenobamate tablets) securing FDA approval and commercial launch in the United States.